Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021)
Entrada Therapeutics' (TRDA) quarterly Accumulated Depreciation came in at $1.4 million in Q4 2021, up 275.6% year-on-year from $377000.0 in Q4 2020, and up 34.6% quarter-over-quarter from $1.1 million in Q3 2021.
Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2021.
- On a quarterly basis, Accumulated Depreciation rose 275.6% year-over-year to $1.4 million in Q4 2021; TTM through Dec 2021 was $1.4 million, a 275.6% increase from a year earlier, with the FY2021 full-year figure at $1.4 million, up 275.6% from the prior year.
- Accumulated Depreciation advanced to $1.4 million in Q4 2021 per TRDA's latest filing, from $1.1 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $1.4 million in Q4 2021 and bottomed at $377000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Dec 31, 2020 | 377,000.00 |